Whipple’s Disease Market Research Report - Global Forecast till 2027

Whipple’s disease market information: by diagnosis (physical exam, biopsy, and others), by treatment (medications, supplements, and others), by end user- global forecast till 2027

ID: MRFR/Pharma/2762-HCR | February 2021 | Region: Global | 80 pages

Please note that the assessment period of report has been updated from 2016- 2023 to 2020-2027. Cordially fill Sample form for updated data.

Market Synopsis of Global Whipple’s disease Market

Market Scenario

Whipple’s disease (WD) is a rare, chronic, systemic infectious bacterial disease caused by Tropheryma whipplei that affects gastrointestinal system, especially,  the small intestine. The infection may spread to any part of the body but mostly it affects the central nervous system, joints, lungs, heart, and eyes. Some common symptoms of this disease are weight loss, diarrhea, abdominal cramping and pain, weakness, fatigue, anemia, inflamed joints, and some other less common symptoms. The prevalence is one in one million people. The prevalence of this diseases is more in men than women.

Ongoing research and clinical trial to find effective cure drive the growth of market. Advancement in medical technology and increasing awareness about this disease boost the market growth.

The global Whipple’s disease market is expected to grow at the CAGR of ~3.1% during the forecast period and is estimated to reach USD 255.3 million by 2023.



Sources: The National Institute of Diabetes and Digestive and Kidney Diseases Health Information Center, The National Institute of Neurological Disorders and Stroke (NINDS), National Center for Biotechnology Information (NCBI), National Organization for Rare Disorders, Inc, Directorate of Industries, annual report, white paper, company presentation

Research Methodology

 Sources: The National Institute of Diabetes and Digestive and Kidney Diseases Health Information Center, The National Institute of Neurological Disorders and Stroke (NINDS), National Center for Biotechnology Information (NCBI), National Organization for Rare Disorders, Inc, Directorate of Industries, annual report, white paper, company presentation


Key Players in the Global Whipple’s Disease Market                                  

Some of the key players in this market: AbbVie Inc. (US), Allergan (Republic of Ireland), Bayer AG (Germany), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Henry Schein, Inc (US), Pfizer Inc. (US)


The global Whipple’s disease market is segmented on the basis of diagnosis, which includes physical exam, biopsy, blood tests, polymerase chain reaction, endoscopy, and others. Biopsy plays important role in diagnosis of this disorder, these tests include needle biopsy, CT-guided biopsy, ultrasound-guided biopsy, aspiration biopsy (fine-needle aspiration), skin biopsy, surgical biopsy, and others. Blood tests sub-segmented into Complete blood count (CBC), Red Blood Cell Count (RBC), serum albumin test, total protein test, and others.

On the basis of treatments, the market is segmented into medications, supplements, and others. Medications is sub-segmented into Intravenous (IV) ceftriaxone (Rocephin), Intravenous (IV) penicillin, sulfamethoxazole-trimethoprim, SMX-TMP, oxycycline (Vibramycin), hydroxychloroquine (Plaquenil), and others. Supplements include vitamin supplements, mineral supplements, and others.

On the basis of end user, it is segmented into hospitals & clinics, academic institutes, medical research centers, and others.

Regional Analysis of the Global Whipple’s Disease Market                  

The Americas holds the largest share in the global Whipple’s disease market. North American region, especially, the US dominates the market in this region. It is a rare disease and found in around less than one in million people in US. Some other factors such as advanced medical facilities, ongoing research and clinical trials, and availability of skilled health professionals. Increasing awareness about this disease in Latin America drives market growth in this region.

The new cases of this disease is increasing in Europe. Availability of advanced diagnostic and therapeutic options, high awareness among the European population, and availability of skilled medical professional drive the European market. Availability of cost-effective of treatment in East European countries, for instance,  Poland than the other parts of the region add fuel to the growing demand. Owing to availability of cost-effective treatment, patients from Western European countries and Russia travel to East and Central European countries to treat this disease.

Asia Pacific region shows low prevalence of the disease. Increasing awareness about this disease in the Asian population leads the market growth. The rapidly developing healthcare sector is another major driver of the market. Due to rapid economic growth, rising middle class population, and their spending on healthcare and related services add fuel to the growth of this market.

Owing to lack of awareness about the disease, slow healthcare infrastructure development, and limited access to required medical facilities, the Middle East & Africa market is growing slower as compared to the global average. On the other hand, due to developed healthcare facilities and government support to improve public health, the Middle East countries such as the UAE dominates market of this region.

Intended Audience

  • Whipple’s Disease Diagnostic and Treatment Supplies Companies

  • Whipple’s Disease Diagnostic and Treatment Supplies Providers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


Frequently Asked Questions (FAQ) :

Whipple’s disease market is projected to grow at a 3.1% CAGR between 2016-2023.

The Americas is expected to dominate the whipple’s disease market.

Whipple’s disease market is predicted to touch USD 255.3 million by 2023.

Major end users of whipple’s disease market include medical research centers, academic institutes, hospitals and clinics, and others.

Some common symptoms of whipple’s disease include inflamed joints, anemia, fatigue, weakness, weight loss, and others.

1. Report Prologue

2. Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

2.3 Market Structure

2.4. Market Segmentation

3. Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

3.5 Forecast Model

4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Mega Trends

4.5 Macroeconomic Indicators

5. Market Factor Analysis

5.1 Value Chain Analysis

5.2 Porters Five Forces Analysis

5.3 Demand & Supply: Gap Analysis

5.4 Pricing analysis

5.5 Investment Opportunity Analysis

5.6 Merger and Acquisition Landscape

5.7 Upcoming Trends

6. Global Whipple’s Disease Market by Diagnosis

6.1 Physical exam

6.2 Biopsy

6.2.1 Needle biopsy

6.2.2 CT-guided biopsy

6.2.3 Ultrasound-guided biopsy

6.2.4 Aspiration biopsy (fine-needle aspiration)

6.2.5 Skin biopsy

6.2.6 Surgical biopsy

6.2.7 Others

6.3 Blood tests

6.3.1 Complete blood count (CBC)

6.3.2 Red Blood Cell Count (RBC)

6.3.3 Serum Albumin Test

6.3.4 Total protein test

6.3.5 Others

6.4 Polymerase Chain Reaction

6.5 Endoscopy

6.6 Others

7. Global Whipple’s Disease Market by Treatment

7.1 Medications

7.1.1 Intravenous (IV) ceftriaxone (Rocephin)

7.1.2 Intravenous (IV) penicillin

7.1.3 Sulfamethoxazole-trimethoprim

7.1.4 SMX-TMP

7.1.5 Oxycycline (Vibramycin)

7.1.6 Hydroxychloroquine (Plaquenil)

7.1.7 Others

7.2 Supplements

7.2.1 Vitamin supplements

7.2.2 Mineral supplements

7.2.3 Others

7.3 Others

8. Global Whipple’s Disease Market by End User

8.1 Hospital and clinics

8.2 Academic institutes

8.3 Medical Research centers

8.4 Others

9. Global Whipple’s Disease Market by Region

9.1 Introduction

9.2 Americas

9.2.1 North America The US Canada

9.2.2 Latin America

9.3 Europe

9.3.1 Western Europe Germany France Italy Spain UK Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia

9.4.1 China

9.4.2 India

9.4.3 Japan

9.4.4 South Korea

9.4.5 Rest of Asia

9.5 Pacific

9.6 Middle East & Africa

9.6.1 UAE

9.6.2 Saudi Arabia

9.6.3 Egypt

9.6.4 Rest of the Middle East & Africa

10. Competitive Landscape

11. Company Profile

11.1 AbbVie Inc.

11.1.1 Overview

11.1.2 Product/Business Segment Overview

11.1.3 Financial Updates

11.1.4 Key Developments

11.2 Allergan

11.2.1 Overview

11.2.2 Product/Business Segment Overview

11.2.3 Financial Updates

11.2.4 Key Developments

11.3 Bayer AG

11.3.1 Overview

11.3.2 Product/Business Segment Overview

11.3.3 Financial Updates

11.3.4 Key Developments

11.4 Bristol-Myers Squibb Company

11.4.1 Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Updates

11.4.4 Key Developments

11.5 F. Hoffmann-La Roche Ltd

11.5.1 Overview

11.5.2 Product/Business Segment Overview

11.5.3 Financial Updates

11.5.4 Key Developments

11.6 Henry Schein, Inc

11.6.1 Overview

11.6.2 Product/Business Segment Overview

11.6.3 Financial Updates

11.6.4 Key Developments

11.7 Henry Schein, Inc

11.7.1 Company Overview

11.7.2 Product/Business Segment Overview

11.7.3 Financial Updates

11.7.4 Key Development

11.8 Others

12. Conclusion

12.1 Key findings

12.1.1 From CEO’s viewpoint

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Whipple’s Disease Market

13. Appendix